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INTRODUCTION
Adjuvant chemotherapy can improve disease outcome in 
early breast cancer; however, its appropriate method of appli-
cation is still a matter of debate. In addition to the most com-
monly used anthracycline and taxane derivatives, other cyto-
toxic agents and targeted therapies can be administered. In 
the last few years, the preoperative introduction of chemo-
therapeutic regimens has become a general approach in the 
clinical practice [1]. The main purpose of the neoadjuvant 
therapy (NAT) is to reduce the size of the primary tumor, 
eventually allowing radical or more conservative surgical in-
terventions [2]. NAT also allows an early evaluation of clinical 
efficacy; thus, changes in the applied chemotherapeutic regi-
men can be commenced at a relatively early stage [3]. The aim 
of this work is to collect relevant neoadjuvant trial results that 
may assist physicians to apply optimal treatment for patients 
with breast cancer.  
CLINICAL RELEVANCE OF PATHOLOGICAL 
COMPLETE RESPONSE
Early randomized trials comparing NAT with adjuvant che-
motherapy failed to detect any improvement in overall surviv-
al (OS) rates [4]. On the other hand, clinical trial data have 
suggested that pathological complete response (pCR) ob-
served after NAT, may result in higher survival rates. Howev-
er, it should be pointed out that in these early trials, the defini-
tion of pCR was inconsistent. In line with the currently ac-
cepted definition, pCR denotes a condition when residual tu-
mor is neither detected in the breast, nor in the axilla. However, 
according to several investigators, in-situ remnant in the breast 
is acceptable.
In the meta-analysis published by Cortazar et al. [5], a total 
number of 12 international controlled trials were evaluated, 
yielding a pooled population of 11,955 patients. This meta-
analysis revealed that patients with pCR (ypT0/ypN0) had su-
perior event-free survival (EFS) and OS. This prognostic cor-
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In the last few decades, neoadjuvant therapy for breast cancer 
has gained considerable therapeutic importance. Despite exten-
sive clinical investigations, it has not yet been clarified whether 
neoadjuvant therapy would result in improved survival in com-
parison with the standard adjuvant setting in any subgroups of 
patients with breast cancer. Chemotherapy is especially effective 
in the treatment of endocrine insensitive tumors, and such ther-
apeutic benefit can be assumed for patients with triple-negative, 
or hormone receptor-negative and human epidermal growth fac-
tor receptor 2 (HER2)-positive breast cancer. However, dose es-
calation, modification of the therapeutic regimens according to 
early tumor response, as well as the optimal sequence of admin-
istration are still matters of debate. There is a current debate be-
tween clinical experts regarding the concomitant and sequential 
administration of carboplatin and capecitabine, respectively, as 
part of the standard neoadjuvant treatment, as well as the use of 
bevacizumab, as part of the preoperative treatment. In case of 
HER2 positive tumors, an anti-HER2 agent can be administered 
as part of the preoperative treatment, and according to prelimi-
nary clinical data, dual HER2 blockade can also be reasonable. 
Further, chemotherapy-free regimens can be justified in highly 
endocrine sensitive tumors, while immune modulating agents 
may also gain particular importance in the case of certain sub-
types of breast cancer. Several small-molecule targeted ther-
apies are under clinical investigation and are expected to provide 
new neoadjuvant treatment options. However, novel, more pre-
dictive biomarkers are required for further evaluation of the neo-
adjuvant therapies, as well as the effect of novel targeted agents 
intended to be incorporated into neoadjuvant therapy.  
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relation was most prominent for patients who presented de-
differentiated, triple-negative (TN), and human epidermal 
growth factor receptor 2 (HER2)-positive (HER2+) tumors; 
in case of HER2 positivity, trastuzumab therapy was adminis-
tered. To assess the utility of pCR for neoadjuvant anti-HER2 
therapies, Broglio et al. [6] performed a patient-level analysis 
on 38 trials with 5,768 patients that compared the EFS and OS 
hazard ratios in pCR and non-pCR patients. Patients with 
pCR had significantly longer EFS compared to non-pCR 
(hazard ratio, 0.37), and that was more pronounced in case of 
hormone receptor negativity (hazard ratio, 0.29) and after 
neoadjuvant anti-HER2 therapy (hazard ratio, 0.35). The same 
magnitude of positive effect of pCR was also observed after 
OS evaluation (hazard ratio, 0.34).
It has been claimed though, that the clinical evidence does 
not support pCR rate as an early predictor factor for OS. Al-
though patients generally may expect a longer survival after 
pathological complete remission, in individual trials, pCR rate 
defined as a surrogate endpoint, may not predict survival [7]. 
Cortazar et al. [5], found no significant association between 
the frequency of pCR and survival data, when trials were sep-
arately analyzed. 
In another meta-analysis published by Berruti et al. [8], data 
from 29 trials (14,641 patients, 59 arms and 30 comparisons) 
were evaluated. This study demonstrated a weak association of 
pCR rates with disease-free survival (DFS) and OS. This asso-
ciation, however, reached statistical significance when intensi-
fied dose-dense and standard-dose regimens were compared. 
From a regulatory perspective, the Food and Drug Admin-
istration (FDA) and the European Medicines Agency (EMA) 
acknowledged pCR as a surrogate endpoint in clinical trials 
performed as part of the development of new drug products 
in certain high-risk subgroups. In accordance therewith, the 
majority of the NAT trials defined pCR as a primary endpoint.
SUBGROUP DIFFERENCES IN NAT TRIALS
In general, the efficacy of NAT largely differs between sub-
groups of patients with different subtypes of breast cancer. 
Von Minckwitz et al. [9] reported a meta-analysis of seven 
NAT trials, yielding a pooled population of 6,377 patients. The 
main finding of this analysis was that patients’ hormonal re-
ceptor (HR) and HER2 status profoundly influences pCR rate 
and survival, after demonstrating a higher pCR rate in HR-
negative (HR–) tumors than in HR-positive (HR+) tumors. 
Moreover, the lowest pCR rate was found among patients with 
luminal A type tumors (6.4%), higher rate in luminal B type 
tumors (11%–22%), and a maximal pCR rate was observed in 
the groups of HER2+ and TN patients (27%–32%). In luminal 
B type, HER2+ and TN tumors patients with pCR had signifi-
cantly higher OS compared to other subtypes. These observa-
tions were also confirmed by the previously mentioned meta-
analyses [5,6].
The TN breast cancer (TNBC) subgroup can be divided 
into smaller subgroups on the basis of genetic differences [10]. 
Gene expression analysis of 386 tumor samples has revealed 6 
distinct subtypes of TNBC: two basal-like (BL1 and BL2), an 
immuno-modulatory (IM), a mesenchymal (M), a mesenchy-
mal stem-like (MSL), and a luminal androgen receptor (LAR) 
subtype. Eleven of the analyzed TN tumor samples were re-
ported as unclassified (UNC). According to the PAM50 classi-
fication, the BL1, BL2, IM, and M subtypes are largely basal-
like, the MSL subtype is largely normal-like, and the LAR sub-
type is mostly comprised of luminal and HER subtypes [11]. 
The efficacy of anthracycline and taxane containing NAT 
differed between groups of patients with different tumor sub-
types [12]. The highest pCR rate was found in BL1 (50%), and 
the lowest in BL2 and LAR (0%–10%) subgroups. The same 
analysis demonstrated that tumor-subtypes can provide a ba-
sis for different therapeutic approaches. The BL1, IM, and 
UNC subtypes are considered to be highly sensitive to geno-
toxic anticancer agents. Therefore, they can be treated with 
platinum-based chemotherapeutic regimens, as well as with 
poly ADP-ribose polymerase (PARP) inhibitors [12]. Even 
though, there is no clear association between the IM subtype 
and the presence of tumor infiltrating lymphocytes (TIL), 
gene expression data of immunological relevance show corre-
lation with TILs [11]. Regarding the LAR subtypes, antian-
drogen agents and phosphoinositide 3-kinase (PI3K) inhibi-
tors can be used effectively due to the high PI3K catalytic sub-
unit alpha (PIK3CA) mutation rate (40% vs. 4% in other sub-
types). The M subtype was found to respond to the treatment 
with the SRC inhibitor dasatinib. Furthermore, PI3K-, protein 
kinase B (AKT)-, mammalian target of rapamycin (mTOR)-, 
mitogen-activated protein kinase kinase (MEK)-, cell cycle- 
and growth factor-inhibitors are also assumed to have ther-
apeutic relevance in TNBC [10,12]. In HR+ and HER2-nega-
tive (HER2−) subgroups neoadjuvant chemotherapy is less ef-
fective. Although it may have role, especially in more advanced 
and high-grade tumors, targeted therapies, especially endo-
crine therapy (ET), are generally considered more essential. 
NEOADJUVANT CHEMOTHERAPY: IMPACT OF 
DOSE, COMBINATION AND SEQUENCE
The majority of the relevant guidelines recommend the in-
corporation of anthracyclines and taxanes in NAT regimens 
targeted for breast cancer [13], but there is no agreement on 
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the optimal combination, dose, and sequence. In general, sim-
ilar doses and combinations are used both in adjuvant and 
neoadjuvant settings. Anthracyclines and taxanes have been 
reported to be used both concomitantly and sequentially in 
controlled trials. In a phase III trial, similar efficacy of doxoru-
bicin was observed when combined with either cyclophospha-
mide or docetaxel [14]. In the GEPARDUO trial, a number of 
913 women with untreated operable breast cancer were ran-
domized to receive either four cycles of doxorubicin-docetaxel 
combination, or four cycles of doxorubicin-cyclophosphamide 
and subsequently, four cycles of docetaxel. Although the sub-
sequent administration of doxorubicin and docetaxel resulted 
in a significantly higher pCR rate (14.3%) compared to the 
concomitant administration thereof (7%), the authors attrib-
uted this effect to the longer duration of the sequential therapy 
[15]. In contrast, Vriens et al. [16] found that adding four cy-
cles of docetaxel sequentially to four cycles of doxorubicin-cy-
clophosphamide does not significantly improve the pCR rate, 
while it causes higher rate of grade 3 to 4 sensory neuropathy 
(5% vs. 0%). Further, in the BCIRG-005 adjuvant trial, 3,298 
patients were enrolled, and similar DFS and OS values were 
reported after concomitant and sequential therapy [17]. On 
the other hand, the NSABP B-30 trial showed slightly higher 
survival rates for sequential therapy [18]. Since trials failed to 
clearly demonstrate the superiority of either approach, both 
types of administration are accepted during NAT; though, 
most practitioners prefer sequential therapy.
It is also unclear whether dose-dense therapy is superior to 
conventional schemes or not. According to the National 
Comprehensive Cancer Network (NCCN) guidelines, the 
dose-dense therapy is preferred, although this approach is 
questioned by some experts [19]. In a recent meta-analysis 
published by Petrelli et al. [20], it was found that dose-dense 
therapy in a NAT setting resulted in a significantly higher 
pCR rate, but had no significant effect on DFS and OS [20]. 
Based on the meta-analysis of four adjuvant clinical trials en-
rolling 3,418 patients in total, Lemos Duarte et al. [21] have 
found that dose-dense therapy led to a significant improve-
ment in DFS irrespective of HR status, but had no significant 
influence on OS. A more comprehensive meta-analysis of 
eight adjuvant trials, recruiting a total number of 17,188 adult 
women with resected BC, was subsequently published by Petrelli 
et al. [22]. This analysis concluded that dose-dense therapy 
was associated with significantly higher DFS and OS. However, 
only the HR negative subgroup showed a significant improve-
ment regarding OS.
Although significant effect of dose-dense therapy was ap-
parent only when it was adjuvantly applied, the meta-analyses 
reported similar hazard ratios for OS; 0.89 for the NAT [20] 
and 0.86 for the adjuvant [22] therapy. This finding introduces 
the possible use of dose-dense regimes in the neoadjuvant set-
ting, at least for patients with HR− tumors.
According to current therapeutic standards, the combina-
tion of doxorubicin or epirubicin and docetaxel or paclitaxel 
is highly recommended [14,23-26]. The exact therapeutic role 
of newly developed chemotherapeutic agents is still under in-
vestigation. 
In the GEPARSIXTO trial, a pCR rate of 37% was observed 
in patients receiving liposomal doxorubicin plus paclitaxel in 
a weekly basis. Upon this result, the combination of liposomal 
doxorubicin and paclitaxel has become an alternative to an-
thracycline in NAT [27]. The phase III GEPARSEPTO trial 
reported the enrolment of 1,206 patients who were randomly 
assigned to receive either nab-paclitaxel or paclitaxel before 
epirubicin-cyclophosphamide treatment. Although, signifi-
cantly higher pCR rate was observed in the nab-paclitaxel arm 
(38% vs. 29%, respectively), the rate of grade 3 to 4 sensory 
neuropathy was also higher in this group [28]. However, this 
finding failed to be endorsed by the ETNA trial, which en-
rolled 602 patients and found similar pCR rates in the nab-
paclitaxel and paclitaxel arms [29]. It is noteworthy though, 
that in the ETNA trial, the introduction of anthracycline regi-
men was optional and depended on the decision of the treat-
ing physician, who could biased the overall conclusion on the 
efficacy of nab-paclitaxel. Nevertheless, the clear therapeutic 
benefit of nab-paclitaxel is still unclear. The results of the 
NEOTANGO trial have proven the superiority of the taxane-
anthracycline sequence. In this 4-arm trial, the sequence of 
epirubicin-cyclophosphamide combination and paclitaxel, 
and the rationale of the add-on gemcitabine therapy were 
questioned. After a 47-month median follow-up of 831 pa-
tients, the pCR rate was significantly higher when NAT was 
started with paclitaxel, than with the epirubicin-cyclophos-
phamide combination (20% vs. 15%). The administration of 
gemcitabine had no influence on the pCR rate [30]. However, 
other studies found no evidence supporting that the order of 
administration of anthracyclines and taxanes would affect 
therapeutic outcome of HER2+ patients [31]. Bines et al. [32] 
analyzed the results provided by studies of adjuvant and neo-
adjuvant chemotherapeutic settings, and concluded that tax-
anes are more beneficial when administered at first. For this 
reason, they recommended its use in routine clinical practice.
ADAPTED STRATEGIES IN NAT
The revision of the applied NAT strategies on the basis of 
newly published evidence, is frequently driven by the inten-
tion to improve therapeutic effectiveness. The choice of ther-
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apeutic strategies can be based on tumor characteristics, in-
cluding HR and HER2 status, genetic subtypes, or alterations, 
as well as on early response evaluation, commonly via the re-
sponse guided therapy. Even though the approach to adjust 
therapy according to early response seems logical in case of 
poorly or nonresponding patients, its routine use in the clini-
cal practice has not yet been established. 
The WSG-ADAPT is an ongoing “umbrella” trial in the 
frame of which, 4,936 patients are projected to enroll and as-
sign in four subtrial groups (4,000 patients in HR+/HER2−, 
380 patients in HR+/HER2+, 220 patients in HR−/HER2+, 
and 336 patients in TN subgroup). Subtrials focus on the 
identification of early surrogate markers for subgroup adapted 
therapy success in the neoadjuvant setting [33]. The main ra-
tionale of this study is substantiated by the clinical observation 
indicating that a part of HR+ tumors are good candidates for 
neoadjuvant chemotherapy, especially those with high-risk 
features, like advanced grade, high Ki-67 or HER2 positivity 
[34]. In contrast, well-differentiated HR+ tumors, especially 
those with lobular histology, are improbable to respond to 
chemotherapy and are good candidates for endocrine and 
other targeted therapies. 
The GEPARTRIO trial investigated the DFS and OS after 
response-guided theory in patients with early breast cancer. A 
total number of 2,072 patients were enrolled and received two 
cycles of docetaxel-doxorubicin-cyclophosphamide (TAC). 
Patients considered as early responders (roughly 2/3 of pa-
tients) were randomized to receive an additional four or six 
cycles of TAC. Nonresponder subjects were randomized to 
four cycles of TAC or vinorelbine-capecitabine (NX) combi-
nation. Among early responders, eight cycles of TAC resulted 
in significantly higher OS compared to the OS after six cycles 
of TAC. This difference was most prominent among HR+ pa-
tients. In general, results proved the superiority of response-
guided (8× TAC or TAC-NX) chemotherapy [35]. 
Response-guided therapy was also applied in the GEPAR-
QUINTO trial. Patients with HER2− tumors were firstly ran-
domized to receive four cycles of epirubicin-cyclophosph-
amide with or without bevacizumab. Then, four cycles of 
docetaxel with or without bevacizumab were administered to 
patients with clinical response, while nonresponders received 
weekly paclitaxel 12 with or without everolimus. Although 
this study design did not allow the assessment of the benefit of 
the response-guided therapy, the application of this therapy as 
a recognized therapeutic approach, could be concluded from 
this trial setting [36]. 
In a trial conducted by Wang-Lopez et al. [37], a number of 
264 previously untreated stage II–III operable patients with 
breast cancer were randomized to three cycles of 5-fluoroura-
cil-epirubicin-cyclophosphamide combination (FEC), fol-
lowed by three cycles of docetaxel, or to receive response-
guided treatment. In the response-guided arm, the first evalu-
ation occurred after two or four additional cycles of FEC. Pa-
tients with insufficient response (i.e., < 30% or < 50% tumor 
size decreases after two or four cycles of FEC, respectively) 
were switched to a total of four or two cycles of docetaxel. Pa-
tients with sufficient response received six cycles of FEC. No 
significant differences were found between study arms in 
terms of breast conserving surgery and pCR rates. These find-
ings support that docetaxel can improve treatment efficacy, 
even in the case of relatively resistant tumors, while it remains 
unclear whether responders and nonresponders should be 
treated differently. 
In order to explore the benefit of switching between differ-
ent therapeutic regimens—adapting the treatment to the clini-
cal situation—studies comprising a control arm, including pa-
tients treated conventionally irrespective of early tumor re-
sponse seem more appropriate, since they allow for evaluation 
of the benefit of the alternative therapeutic approach. Howev-
er, when comparing therapeutic regimens considered equally 
efficacious, the cross-over design is also a feasible alternative. 
As examples, PREDIX HER2 (NTC02568839) and PREDIX 
LUMB (NCT02603679) trials are cited. In both trials, after 
early disease evaluation, patients either remained in the same 
arm, or if no response was proven, they crossed over to the 
comparator arm.
In case of HR+ tumors, the role of chemotherapy in early 
setting is debated. In the WSG-ADAPT trial, patients with 
HR+/HER2− tumors were treated with ET for 3 months. 
Then, the low risk patients with good response were assigned 
to further ET, while the high-risk patients, showing poor re-
sponse, received chemotherapy [33]. In ALTERNATE trial 
(NCT01953588), anastrozole, fulvestrant, or their combina-
tion were used during the 12-week induction period. Then, 
ET was either continued in patients responding to the induc-
tion phase, or therapy was switched to paclitaxel for a 12-week 
period.
ADDITIONAL CYCLES OVER STANDARD 
THERAPY
There is not enough evidence justifying the benefits of che-
motherapies exceeding standard length. Therefore, current 
guidelines do not recommend extended chemotherapies, in-
cluding those applied postoperatively. In the GEPARQUATTRO 
trial, the authors have concluded that longer therapy is not 
beneficial; however, lower doses of docetaxel were applied 
[38]. On the other hand, the GEPARTRIO trial has found that 
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chemotherapy administered over a prolonged period (i.e., 
8× TAC vs. 6× TAC) is more efficacious [39].
In a pooled analysis of seven German neoadjuvant trials, 
higher pCR rate was associated with an increase in the num-
ber of chemotherapy cycles and cumulative doses of anthra-
cyclines and taxanes, as well as with the add-on capecitabine 
and trastuzumab treatment. These observations, together with 
similar findings from other studies, indicated that more inten-
sified neoadjuvant treatment could improve patients outcome, 
at least in selected cases [40]. 
Another example is the CREATE-X phase III adjuvant trial, 
where 455 HER2− patients with residual disease after NAT 
were randomized either to receive eight cycles of capecitabine, 
or no additional chemotherapy [41]. Capecitabine treatment 
resulted in significantly higher 5-year DFS and OS, compared 
to the control arm. This difference was the most pronounced 
in the TN subgroup. However, this approach needs to be fur-
ther investigated, especially in patients with poor prognosis, 
such as patients with TN cancer showing non-pCR response. 
INCORPORATING ADDITIONAL AGENTS INTO 
NAT REGIMENS
Dual blockade in HER2+ tumors
In case of HER2+ breast cancer treatment, the incorpora-
tion of trastuzumab into NAT resulted in higher pCR and 
better survival [8]. Although it has not yet been proven, it has 
been suggested that trastuzumab would be more efficacious 
when administered preoperatively than postoperatively. The 
evidences of a higher rate of pCR observed for trastuzumab 
containing combinations, and the more favorable results with 
early administration of trastuzumab, set the neoadjuvant 
trastuzumab as an accepted scenario. The optimal chemo-
therapy backbone was also questioned in several trials, but the 
strong additive effect of trastuzumab is generally accepted. 
Achieving dual HER2 receptor blockade by adding lapatinib 
or pertuzumab to trastuzumab, significantly increased pCR 
rate to 50% to 60%, as observed in relevant trials [42-47]. 
However, therapeutic benefit manifested mainly in case of 
HR− tumors [9,45]. These trials have not yet demonstrated 
whether the higher pCR rate would result in higher OS 
[40,42].
The results of the GEPARQUINTO [48] and CALGB 40601 
[45] trials indicated that trastuzumab is more effective than 
lapatinib, whereas the NeoALTTO [44] and NSABP-B41 [47] 
trials reported no significant difference between lapatinib and 
trastuzumab treatments. Nevertheless, while approximately 
one third of patients discontinued lapatinib due to adverse 
events, the trastuzumab-pertuzumab combination is more ac-
cepted. 
In the phase III NSABP B-52 study, 315 HR+ and HER2+ 
patients were randomized to be given docetaxel, carboplatin 
(CBP), trastuzumab, and pertuzumab with or without oestro-
gen deprivation therapy (aromatase inhibitor and luteinizing 
hormone-releasing hormone [LHRH] analogue if premeno-
pausal). In the investigational arm, the pCR rate was not sig-
nificantly higher (40.9% vs. 46.1%) along with similar toxicity 
profile, suggesting that ET is not important for dual HER2-
blockade and chemotherapy [49].
Oral HER2 blockers are under clinical investigation. Early 
results obtained with pan-HER blocker afatinib and irrevers-
ible HER2 blocker neratinib indicated the therapeutic efficacy 
of these compounds. However, their superiority over lapatinib 
has not yet been established [50,51]. 
Chemo-free NAT or ET after NAT
The pCR rate in HR+ tumors is significantly lower compared 
to other subtypes. This finding raises the question whether che-
mo-free therapy is reasonable. In the phase II TBCRC006 trial, 
trastuzumab and lapatinib were combined either with letrozol 
or LHRH analogue, according to HR and menopausal status. 
Overall, the pCR rate was 21% for HR+ tumors [52], while 
pCR rates obtained for HR+ patients in the NeoSphere trial 
were lower for trastuzumab-pertuzumab combination (5.9%), 
similar for trastuzumab-docetaxel or pertuzumab-docetaxel 
combinations (17.4%–20%), and higher for trastuzumab-per-
tuzumab-docetaxel triple combination (26%) [43]. 
These findings suggest that it would be too early to omit 
chemotherapy in HER2+ tumors, even though they are HR+ 
(Table 1). Otherwise, investigators of the TBCRC 006 trial re-
ported that the minimal residual disease after NAT is more 
common in HR+ (33%) than in HR− tumors (4%). Overall, 
54% of patients achieved a good response in this trial. Know-
ing that pCR is only a prognostic factor in HR- tumors, che-
mo-free protocol may be an option for HR+ patients despite 
the low rate of pCR. 
In the WSG-ADAPT trial, 380 patients with HER2+ and 
HR+ tumors were randomized in order to receive trastuzum-
ab-emtansine (TDM1) monotherapy, TDM1 with ET, or 
trastuzumab with ET, which resulted in pCR rates of 40.5%, 
45.8% and 6.7%, respectively. The pCR rate was significantly 
higher with TDM1, than with the trastuzumab containing 
chemo-free arm. Addition of ET to TDM1 had no significant 
effect [53].
The KRISTINE trial also confirmed that the more intensive 
chemotherapy was associated with improved efficacy. In this 
study, 444 patients were enrolled and randomized to receive 
six cycles of TDM1 and pertuzumab, or six cycles of docetaxel, 
124  Gábor Rubovszky, et al.
http://ejbc.kr https://doi.org/10.4048/jbc.2017.20.2.119
CBP, trastuzumab, and pertuzumab; pCR rates of 44.4% and 
55.7% have been achieved, respectively. The difference was 
apparent in HR+ subgroup (37.9% vs. 44.8%), but it was more 
pronounced between HR− subgroups (53.8% vs. 72.4%) [54]. 
It is expected that the randomized HELEX study (extension 
of TBCRC006) will provide additional data regarding the 
chemo-free treatment of HER2+ tumors (NCT00999804).
The effect of PIK3CA mutation on the success of the ther-
apy was investigated in several trials (GEPARQUINTO, 
GEPARSIXTO [27], NeoALTTO, and CherLOB [55]). All 
analyses have found lower pCR rates in patients with PIK3CA 
mutation receiving anti-HER2 containing regimens. Similar 
findings have been reported irrespectively of the administered 
anti-HER2 agent or HR status [9,56-58]. In a subgroup analy-
sis performed on the dataset of the NeoALTTO trial, PIK3CA 
mutational status, hormone status, and therapeutic approach 
(single or dual HER2-blockade) were identified as indepen-
dent predictive factors of pCR. This finding would imply that 
anti-HER2 therapy is reasonable in PIK3CA mutant tumors, 
as well. In addition, the possibility of targeting the PI3K-
mTOR pathway has also emerged [56].
Additional chemotherapeutic agents 
The efficacy of platinum derivatives, such as cisplatin or 
CBP, in the treatment of breast cancer has been demonstrated 
by clinical trials. In the phase II GEPARSIXTO study, 588 
patients with TN and HER2+ patients were recruited and 
randomized to receive weekly paclitaxel and liposomal 
doxorubicin with or without CBP. The benefit of addition of 
CBP was apparent only in a subgroup of patients presenting 
TN tumors, as reflected from significantly improved pCR 
rates (53.2% and 36.9% for CBP-supplemented and CBP-free 
therapies, respectively) [27].
This finding was endorsed by the phase II CALGB 40603 
trial, which enrolled patients with TNBC. Subjects were ran-
domized according to a 2× 2 factorial design to receive neo-
adjuvant paclitaxel± CBP± bevacizumab, followed by dose-
dense doxorubicin plus cyclophosphamide ± bevacizumab. 
Analysis of the results has shown that only CBP improved sig-
nificantly the pCR rate, from 41% to 54%. The bevacizumab-
containing arms had a combined pCR rate of 59% compared 
with 48% in the bevacizumab-free arms. The arm that includ-
ed both CBP and bevacizumab had the highest pCR rate 
(67%) [59]. 
In the GEPARSIXTO trial, the role of lymphocyte infiltra-
tion has also been investigated. The pCR rates among patients 
receiving CBP were significantly higher in case of tumors 
showing lymphocyte predominance. Similarly, subgroup 
analyses of TN and HER2+ patients also indicated the positive 
association of pCR rates and the presence of lymphocyte infil-
tration. On the other hand, the effects of inclusion of CBP on 
DFS were inconsistent, as reported by these trials. According 
to the GEPARSIXTO trial, patients with TN tumors showed 
significantly higher DFS as a result of CBP-supplemented 
therapy. The CALGB 40603 trial, however, reported no evi-
dence on the improvement of DFS. 
In the open-label, single-arm trial of Sharma et al. [60], a 
number of 76 TNBC patients were treated with four to six cy-
cles of docetaxel and CBP, and results demonstrated in a re-
markably high pCR rate of 66% (55). Although previous neo-
adjuvant trials reported that BRCA mutant tumors were high-
ly sensitive to platinum agents [61], the GEPARSIXTO trial 
Table 1. Pathological complete remission rates in neoadjuvant trials with anti-HER2 blockade on HR-positive breast cancers
Type of neoadjuvant therapy Therapy Trial pCR (%)*
pCR rates in pre-/
post-menopausal 
patients (%)
Chemotherapy+trastuzumab T-DM1 ADAPT (n=119) [53] 41 37.9/44.1
Trastuzumab+docetaxel CALGB40601 (n=70) [45] 41
NeoSphere (n=50) [43] 20
Chemotherapy+dual HER2 blockade T-DM1+pertuzumab KRISTINE (n=138) [54] 35
Trastuzumab+docetaxel+carboplatin+pertuzumab KRISTINE (n=128) [54] 44
Trastuzumab+docetaxel+lapatinib CALGB40601 (n=69) [45] 41
Trastuzumab+docetaxel+pertuzumab NeoSphere (n=50) [43] 26
Chemotherapy+dual HER2 
blockade+endocrine therapy
Trastuzumab+docetaxel+carboplatin+pertuzumab+
aromatase inhibitor
NSABP B-52 (n=157) [49] 46
Chemotherapy+trastuzumab+endocrine 
therapy
T-DM1+endocrine therapy ADAPT (n=127) [53] 41.5 38.1/45
Trastuzumab+endocrine therapy Trastuzumab+endocrine therapy ADAPT (n=129) [53] 15.1 13.6/16.7
Dual HER2 blockade Trastuzumab+pertuzumab NeoSphere (n=51) [43] 6
HER=human epidermal growth factor receptor 2; HR=hormonal receptor; pCR=pathological complete response; T-DM1=trastuzumab emtansine. 
*pCR rate for HER2 positive and estrogen receptor positive tumours (pCR rate in %).
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found no evidence indicating that the presence of BRCA mu-
tation would result in higher efficacy of CBP therapy. These 
results provide a basis for the incorporation of CBP in the 
NAT of patients with TNBCs; in the absence of additional 
data on survival, the routine use of platinum is not recom-
mended, though. Nevertheless, addition of platinum can be 
justified on an individual basis, if certain risk factors are pres-
ent, including high-risk, germ-line BRCA mutation, and lym-
phocyte predominance. 
In the GEPARQUATTRO study, the effect of addition of 
capecitabine to anthracycline- and taxane-based NAT was in-
vestigated. A total number of 1,509 patients (out of which 445 
patients were HER2+) were randomized after four cycles of 
epirubicin-cyclophosphamide, in order to receive an addition-
al four cycles of docetaxel or four cycles docetaxel-capecitabine 
combination, or four cycles of docetaxel followed by four cy-
cles of capecitabine. Neither the addition of capecitabine, nor 
the prolongation of therapy improved the efficacy outcomes as 
reflected from the similar pCR rates (22.3%, 19.5%, and 22.3%, 
respectively) [38]. Similarly, according to the findings of the 
NSABP B-40 trial, the addition of capecitabine or gemcitabine 
did not improve significantly pCR rate or survival [62]. It 
should be noted that both trials applied lower docetaxel doses 
when used in combination with capecitabine. Contrastingly, in 
the ABCSG-24 phase III trial, Steger et al. [63] randomized 
536 patients to receive similar doses of epirubicin-docetaxel 
combination with or without capecitabine. The pCR rate in 
the capecitabine-supplemented arm was 23%, which was sig-
nificantly higher compared to results obtained in the control 
group (15.4%). This result is consistent with findings of the ad-
juvant CBCSG-10 study. This trial was designed to investigate 
the effect of add-on capecitabine therapy in patients sequen-
tially receiving docetaxel and epirubicin. Even though the 
study did not meet its primary endpoint (i.e., DFS), the re-
lapse-free, disease-free, and the OS were found to be higher in 
the capecitabine arm [64]. The therapeutic role of capecitabine 
in the perioperative setting was further endorsed by the CREATE-
X study previously mentioned [40]. These results suggest that 
capecitabine provides therapeutic benefit only when other 
NAT agents are administered in conventional doses. 
Targeted agents other than anti-HER2 or endocrine 
medication
The benefit of add-on bevacizumab in a NAT setting was 
investigated by 3 phase III and 2 phase II randomized trials, 
so far (Table 2). In the GEPARQUINTO trial, which included 
four cycles of epirubicin-cyclophosphamide and docetaxel 
with or without bevacizumab, [36] inclusion of bevacizumab 
in the therapy resulted in significantly higher pCR in patients 
with TNBC, whereas no significant effect was observed in pa-
tients with HR+ tumor. However, the addition of bevacizum-
ab did not demonstrate any significant effect on the survival 
rates (DFS or OS) of the HER2− and TN subgroups. 
The NSABP B-40 trial aimed to investigate the efficacy of 
add-on bevacizumab, capecitabine, and gemcitabine by using 
a 3 × 2 factorial design. In contrast to the findings of the 
GEPARQUINTO trial, in this study, the bevacizumab related 
improvement of pCR was apparent only in patients with HR+ 
tumors. After a median 4.7-year follow-up, bevacizumab 
treatment was associated with higher OS (hazard ratio, 0.65; 
p= 0.004) while DFS was not significantly affected [62]. 
The investigators of the ARTemis trial reported significantly 
higher pCR rate only in the subgroup of 241 patients with 
TNBC [65]. With respect to pCR in bevacizumab treated 
TNBC patients, the phase II CALGB 40603 study found no 
significant differences, while the SWOG S0800 study reported 
significantly higher pCR rates in the add-on bevacizumab 
group [59,66]. In a recent meta-analysis of five randomized 
trials Nahleh et al. [67] found that bevacizumab significantly 
increases the pCR rate, both in TN and HR+ subgroups of pa-
tients. The inclusion of bevacizumab into NAT regimens re-
quires further investigation, as well as analysis of pooled sur-
vival and safety data. 
The antidiabetic agent metformin also seems to have ther-
apeutic value in the neoadjuvant treatment of breast cancer. In 
a small randomized, double-blind trial conducted by Arce-
Salinas et al. [68], patients with HR+/HER2− tumors were 
treated either with metformin or with placebo, in addition to 
the conventional NAT regimen. Metformin treatment resulted 
in a higher pCR rate.
According to the result of a phase II trial on patients with 
TNBC, the addition of CBP and PARP-inhibitor veliparib to 
NAT led to a remarkably higher pCR rate (26% vs. 52%) [69]. 
The therapeutic value of add-on veliparib is under investi-
gation in an ongoing phase III trial (NCT02032277). Similarly, 
rucaparib used in extended adjuvant therapy after NAT has 
also been subjected to an ongoing clinical investigation 
(NCT01074970).
IMMUNOTHERAPEUTIC OPTIONS
Since the recognition that the immune system has the 
greatest potential for the specific destruction of tumors with 
no toxicity, immune-oncology has become a rapidly growing 
field of research. The predictive and prognostic role of TIL 
pointed out the importance of the immune reaction in the 
pathogenesis of breast cancer [70]. Among solid tumors, 
breast cancer has moderate immunogenic properties [71], but 
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the higher mutational rate observed in HER2+ and TN tu-
mors makes these subtypes promising targets for different im-
muno-therapies. 
The higher level of genetic instability and consequently, the 
higher frequency of mutations produce new antigens, which 
eventually lead to increased immunogenicity. A number of 
trials are investigating the role of programmed death protein 1 
and programmed death-ligand 1 inhibitors (pembrolizumab 
[72] or atezolizumab [73]) in breast cancer; so far, promising 
results have been only observed in metastatic breast cancer. In 
addition, antitumor activity in metastatic breast cancer has 
been confirmed using autologous dendritic cell vaccine [74] 
or an antibody-chemotherapy (irinotecan) complex [75], even 
though no data are available regarding its use in neoadjuvant 
setting.
ENDOCRINE THERAPY
About 2/3 of breast cancers are HR+, which makes the use 
of endocrine agents in the neoadjuvant setting reasonable. ET 
alone results in pCR rates less than 10% [76]. However, tu-
mors with high HR expression and low presence of prolifera-
tive markers, such as HER2−, are also associated with low 
pCR rates in standard chemotherapeutic setting. In luminal 
A-like diseases, neoadjuvant ET is a recommended therapeu-
tic option [77], since it leads to a therapeutic response similar 
to that of standard chemotherapy, as observed after a retro-
spective a retrospective analysis using 21-gene recurrence 
scores [78]. Two trials have also compared the efficacy of che-
motherapy and ET, and found that the main endpoints, such 
as OS rate, pCR, and the rate of breast conserving surgery, 
showed no significant difference [79,80]. Furthermore, a re-
cent meta-analysis pooling the data of 3,490 patients, has in-
dicated that clinical and radiological response rates, as well as 
breast conserving surgery rates obtained for neoadjuvant che-
motherapy and ET are similar [81]. Although studies did not 
identify patient subgroup(s) for which neoadjuvant ET could 
be more advantageous than standard chemotherapy, the high-
er toxicity of the latter should be considered during therapy 
planning. 
During treatment, change in Ki-67 value can be a surrogate 
marker for the efficacy of neoadjuvant ET. The preoperative 
endocrine prognostic index (PEPI score) can also serve as a 
basis for selection of patients who could benefit from ET 
alone [76]. The aromatase inhibitors (AI) were found to be 
more effective than tamoxifen. Furthermore, longer preopera-
tive treatment with AIs led to higher pCR rate. Approximately 
one-third of the patients benefited from extended ET (i.e., 
6–12 months), while the probability of progression remained 
low (0.8%–12%). Therefore, 4 to 8 months of AI therapy is 
recommended over tamoxifen in postmenopausal breast can-
cer patients and in selected premenopausal patients who are 
already receiving LHRH-agonist [13,77]. There are several 
ongoing trials investigating the combination of ET and other 
targeted therapies. Using this approach the parallel blockade 
of intracellular pathways and the reversal of endocrine resis-
tance could be achieved. The PI3K/mTOR pathway, CDK4/6, 
HDAC, and immune checkpoints are the most promising and 
widely investigated targets [82]. 
The results of a phase II trial showed that everolimus im-
proved antiproliferative response, but this therapy was associ-
ated with more side effects and no survival data have been 
published, so far [83]. In a phase II trial, HER2− patients re-
ceived lapatinib in addition to letrozol, if wild-type of PI3K 
gene was present. This therapeutic strategy eventually led to 
an increased rate of pCR [84]. Another study with similar de-
sign failed to prove the benefit of add-on gefitinib in anastro-
zole therapy [85]. 
Currently, the following agents are under clinical investiga-
tion: the CDK4/6 inhibitor ribociclib (NCT02712723) and 
palbociclib (NCT02296801, NCT02530424), palbociclib and 
olaparib in a personalized therapy (NCT02624973), the RET 
inhibitor lenvatinib (NCT02562118), the PI3K inhibitor bu-
parlisib (NCT01923168) and taselisib (NCT02273973). 
CONCLUSION
In the last decades, NAT of breast cancer has gained a con-
siderable therapeutic importance. NAT offers several advan-
tages in comparison to standard adjuvant therapies. Provided 
that NAT is commenced during the early phase of the therapy, 
it may allow the possibility to evaluate treatment efficacy and 
avoid ineffective, futile therapy, potentially resulting in im-
proved survival rates, at least in certain subgroups of breast 
cancer. According to our current knowledge, NAT is recom-
mended primarily for resectable TN and HER2+ tumors, and 
consists of anthracycline and taxane components, as well as 
an anti-HER2 agent in presence of HER2 positivity. Although 
in endocrine sensitive tumors, NAT rarely results in pCR, it 
may still provide therapeutic benefit. However, in order to de-
termine the role of NAT in early breast cancer treatment, 
long-term follow-up data provided by clinical trials are re-
quired. It has not yet been clarified whether more intensified 
or long-term administration of NAT regimes, or addition of 
other chemotherapeutic or targeted agents would be benefi-
cial, at least for some well-defined subgroups of patients; such 
conceptions are promising and have been subjected to ongo-
ing clinical investigations. Nevertheless, the therapeutic po-
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tential of NAT is expected to be further improved on the basis 
of biomarker analysis, eventually leading to personalized can-
cer therapy. 
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